187992-16-1

Basic information

• Product Name: (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene
• Synonyms: (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene
• CAS NO: 187992-16-1
• Molecular Weight: 522.644
• Mol File: 187992-16-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene(CAS DataBase Reference)
• NIST Chemistry Reference: (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene(187992-16-1)
• EPA Substance Registry System: (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphthalene(187992-16-1)

Safety Data

• Hazardous Substances Data: 187992-16-1(Hazardous Substances Data)

Upstream product

• 187993-47-1 (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene 
• 105-36-2 ethyl bromoacetate 
• 584-08-7 potassium carbonate 
• 182497-75-2 (+)-(S)-5-Methoxy-1-tetralol 
• 103882-27-5 (R)-(-)-5-methoxy-1,2,3,4-tetrahydro-1-naphthalenamine 
• 861892-54-8 {(R)-5-[(R)-1-(4,5-Diphenyl-oxazol-2-yl)-4-hydroxy-butylamino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid ethyl ester 
• 861892-52-6 (R)-4-(4,5-Diphenyl-oxazol-2-yl)-4-((R)-5-methoxy-1,2,3,4-tetrahydro-naphthalen-1-ylamino)-butan-1-ol 
• 187993-45-9 (1R)-4-hydroxy-1-(4,5-diphenyloxazol-2-yl)butylamine 

Relevant articles and documents

Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: Orally active prostacyclin mimetics. Part 2

Synthetic and biological evaluation of novel diphenyloxazole derivatives containing a pyrrolidine ring, as a prostacyclin mimetic without the PG skeleton, are described. Asymmetric reduction of a ketone using a chiral Ru complex and reductive amination by

4,5-diaryl oxazole derivatives

This invention relates to new heterocyclic compounds, compositions, process of making and method of use thereof for inhibition of platelet aggregation, vasodilation, antihypertensive activity and prostaglandin I2 agonist.